Sickle cell
-
Webinars
COVID-19 & Haemoglobin Disorders: The Impact of Coronavirus on Sickle Cell Disease Patients
An Expert Panel of Six Medical Professionals from various countries, such as India, the UK, Italy and Saudi Arabia, shared their experiences with TIF on the impact of the COVID-19…
Read More » -
TIF Publications
COVID-19 & Haemoglobin Disorders: Compilation of Information for Sickle Cell Disease (2020)
This document compiles information about the coronavirus pandemic specifically addressed to patients with sickle cell disease (SCD).
Read More » -
TIF Publications
COVID-19 & Haemoglobin Disorders: A Classification of Risk Groups & Other Considerations (2020)
A document seeking to offer a risk level classification for thalassaemia and SCD patients in relation to the ongoing COVID-19 pandemic.
Read More » -
News
FDA Grants RMAT Designation to CTX-001™ for the Treatment of Severe TDT β-Thalassaemia & SCD
CRISPR Therapeutics and Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX-001, an investigational, autologous, Gene Editing hematopoietic stem cell therapy, for the treatment of severe Transfusion-Dependent β-Thalassaemia (TDT) and Sickle…
Read More » -
News
FT-4202 Granted FDA Fast Track, Rare Pediatric Disease Designations for SCD
FT-4202, a potential disease-modifying oral treatment for sickle cell disease being developed by Forma Therapeutics, has been given fast track and rare pediatric disease designations by the U.S. Food and Drug Administration (FDA). A fast track status…
Read More » -
News
FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
Global Blood Therapeutics, Inc. announced only a few hours ago that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta™ (previously known as Voxelotor) tablets…
Read More » -
News
Hypertension Medication Valsartan May Help Prevent Vaso-Occlusive Episodes in Sickle Cell Disease
A medication used to treat high blood pressure, called Valsartan, may help decrease the stickiness of red blood cells and reduce the risk of vaso-occlusive crisis in people with sickle cell…
Read More » -
TIF Publications
Beta Thalassaemia, Alpha Thalassaemia and Sickle Cell Disease – Educational Community Booklet (2014)
Eleftheriou A., Angastiniotis M.
Read More » -
TIF Publications
